Peer-reviewed veterinary case report
How Sativex medicine is absorbed and processed in dogs
By Fernández-Trapero, María et al.·Published in Biomolecules·2020·Departamento de Medicina y Cirugí, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
- Species:
- dog
Plain-English summary
A group of adult Beagle dogs was given a new cannabinoid-based medicine called Sativex to see how it affects their bodies. The dogs received either a single dose or multiple doses over 14 days, and blood samples were taken to measure the levels of two active ingredients, CBD and THC. The study found that both ingredients reached their highest levels in the blood within 1 to 2 hours after administration, and there were no significant changes in the dogs' health during the treatment. This research suggests that Sativex could be a potential option for treating various conditions in dogs, but more studies are needed to confirm its effectiveness and safety.
People also search for: Sativex for dogs · CBD THC treatment for dogs · Beagle health studies · cannabinoid therapy for pets
Abstract
The phytocannabinoid-based medicine Sativexis currently marketed for the treatment of spasticity and pain in multiple sclerosis patients and is being investigated for other central and peripheral pathological conditions. It may also serve in Veterinary Medicine for the treatment of domestic animals, in particular for dogs affected by different pathologies, including human-like pathological conditions. With the purpose of assessing different dosing paradigms for using Sativex in Veterinary Medicine, we investigated its pharmacokinetics when administered to naïve dogs via sublingual delivery. In the single dose arm of the study, adult Beagle dogs were treated with 3 consecutive sprays of Sativex, and blood samples were collected at 12 intervals up to 24 h later. In the multiple dose arm of the study, Beagle dogs received 3 sprays daily for 14 days, and blood samples were collected for 24 h post final dose. Blood was used to obtain plasma samples and to determine the levels of cannabidiol (CBD), Δ-tetrahydrocannabinol (Δ-THC) and its metabolite 11-hydroxy-Δ-THC. Maximal plasma concentrations of both Δ-THC (C= 18.5 ng/mL) and CBD (C= 10.5 ng/mL) were achieved 2 h after administration in the single dose condition and at 1 h in the multiple dose treatment (Δ-THC: C= 24.5 ng/mL; CBD: C= 15.2 ng/mL). 11hydroxy-Δ-THC, which is mainly formed in the liver from Δ-THC, was almost undetected, which is consistent with the use of sublingual delivery. A potential progressive accumulation of both CBD and Δ-THC was detected following repeated exposure, with maximum plasma concentrations for both cannabinoids being achieved following multiple dose. Neurological status, body temperature, respiratory rate and some hemodynamic parameters were also recorded in both conditions, but in general, no changes were observed. In conclusion, this study demonstrates that single or multiple dose sublingual administration of Sativex to naïve dogs results in the expected pharmacokinetic profile, with maximal levels of phytocannabinoids detected at 1-2 h and suggested progressive accumulation after the multiple dose treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32054131/